Search results
Showing 1456 to 1466 of 1466 results for pathway
Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund
More than 600 people could benefit from an innovative drug for a form of lung cancer as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund.
Patients should be more involved in decisions about their care, says NICE
A new collaborative, made up of the UK’s leading health care organisations including NICE, has set out plans that will help get patients more involved in decisions about their care.
Patients with blood clots should be treated within 4 hours, says NICE
People who present to hospital with blood clots in the legs or lungs should be offered treatment within 4 hours and have their investigative tests including scans within 24 hours, according to latest guidelines.
How is NICE supporting digital health technology developers?
Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.
Starting with the end in mind - the Innovative Licensing and Access Pathway
Launched in January, the new Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS. It is an exciting development that signals greater collaboration between the agencies involved and, we hope, should bring significant benefits to patients.
Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.
As we launch an early version of the online service, mapping out the regulatory and health technology assessment pathway, Ciara Cook invites future users to help shape this exciting new initiative.
Thousands of lives in England could be saved each year if the NHS follows updated guidance to help it diagnose cancer earlier. Here we outline what the guidance means for GPs.
How NICE can help Clinical Commissioning Groups deliver high quality care
Find out about the range of NICE products that can help Clinical Commissioning Groups deliver high quality care.
NICE recommends adoption of absorbable stitches with antibacterial protection for use on the NHS
NICE estimates an average cost saving of £13.62 per patient to the NHS as a result of reduced surgical site infections compared with current standard absorbable stitches.
Our in-depth articles explore how our work is making a real difference to people’s lives.